Beschreibung:
<jats:p>Type 2 DM in patients with BMIs &gt; 25 is well defined. Gaps exist in understanding lean diabetes (LD), those with BMI &lt; 25. In the US, LD presents in &lt; 12% of patients and most prevalent in minorities. Childhood malnutrition, low socioeconomic status, and early age of onset contribute to this disease variant in developing countries. In Peru, diabetes is estimated to be prevalent in 7% of the population and may be, contrary to some publications, more widespread in remote Amazonian communities where poverty is common and access to health care is lacking. This study identifies characteristics in LD in comparison to individuals with overweight/obese (OOD) type 2 diabetes in Peru. A subsample of individuals with diabetes from a larger pilot study were profiled [F/M = 42/24, age ≥ 18 yrs] in the Amazonian town of Yurimaguas, Peru. We collected glycated hemoglobin (HbA1c), fasting blood lipids panels, height and weight from participants. Diabetes was determined using American Diabetes Association guidelines for HbA1c. In our sample (n = 64), 31.3% of individuals (n = 20) had BMI &lt; 25. HbA1c percentages were significantly higher for LD compared to OOD (11.51%, 9.97% res, p = 0.034). We found no mean difference in age and lipid biomarkers for LD and OOD; for age (54.50 yrs, 53.89 yrs res, p = 0.841), triglycerides (223.56 mg/dL, 218.58 mg/dL res, p = 0.886), LDL (111.97 mg/dL, 114.85 mg/dL res, p = 0.731), HDL (48.12 mg/dL, 48.25 mg/dL res, p = 0.954). The proportion of LD with triglyceride levels &gt; 150mg/dL was less than expected compared to OOD (χ2 = 4.30, df = 1, p = 0.038). We found a larger than expected portion of LD. Consistent with other studies, LD had higher HbA1c levels and less incidences of elevated triglycerides. Elevated blood lipids may be more important when screening OOD. For LD the focus should center on controlling HbA1c levels. Cause for concern is the high number of LD concealed in this study, in a population with a low prevalence of diabetes, and regional physicians could overlook screening in this population.</jats:p>
<jats:sec>
<jats:title>Disclosure</jats:title>
<jats:p>D. C. Robbins: None. B. C. Dean: None. C. Gerhold: None. M. Mosher: None. J. Camargo: None.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Funding</jats:title>
<jats:p>KU Diabetes Institute</jats:p>
</jats:sec>